| Effect of specific lipoprotein (a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography MS Safarova, MV Ezhov, OI Afanasieva, YG Matchin, RV Atanesyan, ... Atherosclerosis Supplements 14 (1), 93-99, 2013 | 137 | 2013 |
| Lipoprotein (a) level and apolipoprotein (a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting MV Ezhov, MS Safarova, OI Afanasieva, VV Kukharchuk, SN Pokrovsky Atherosclerosis 235 (2), 477-482, 2014 | 63 | 2014 |
| Extracorporeal immunoadsorption for the specific removal of lipoprotein (a)(Lp (a) apheresis): preliminary clinical data SN Pokrovsky, AV Sussekov, OI Afanasieva, IY Adamova, AA Lyakishev, ... Chemistry and physics of lipids 67, 323-330, 1994 | 58 | 1994 |
| Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study SN Pokrovsky, IY Adamova, OY Afanasieva Artificial Organs 15 (2), 136-140, 1991 | 55 | 1991 |
| Matrix metalloproteinase 9 as a predictor of coronary atherosclerotic plaque instability in stable coronary heart disease patients with elevated lipoprotein (a) levels M Ezhov, M Safarova, O Afanasieva, M Mitroshkin, Y Matchin, ... Biomolecules 9 (4), 129, 2019 | 51 | 2019 |
| Specific Lp (a) apheresis: A tool to prove lipoprotein (a) atherogenicity SN Pokrovsky, OI Afanasieva, MS Safarova, TV Balakhonova, YG Matchin, ... Atherosclerosis Supplements 30, 166-173, 2017 | 49 | 2017 |
| Association of lipoprotein (a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery SN Pokrovsky, MV Ezhov, LN Il'ina, OI Afanasieva, VY Sinitsyn, ... The Journal of Thoracic and Cardiovascular Surgery 126 (4), 1071-1075, 2003 | 46 | 2003 |
| Lipoprotein (a) apheresis SN Pokrovsky, OI Afanasieva, MV Ezhov Current opinion in lipidology 27 (4), 351-358, 2016 | 31 | 2016 |
| Specific Lipoprotein (a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein (a) levels MV Ezhov, MS Safarova, OI Afanasieva, OA Pogorelova, MI Tripoten, ... Atherosclerosis Supplements 18, 163-169, 2015 | 30 | 2015 |
| Lowering of lipoprotein (a) level under niacin treatment is dependent on apolipoprotein (a) phenotype NV Artemeva, MS Safarova, MV Ezhov, OI Afanasieva, OA Dmitrieva, ... Atherosclerosis Supplements 18, 53-58, 2015 | 24 | 2015 |
| Preparation of affinity sorbents with immobilized synthetic ligands for therapeutic apheresis PA Levashov, OI Afanasieva, OA Dmitrieva, EV Klesareva, IY Adamova, ... Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 4, 303-307, 2010 | 24 | 2010 |
| Therapeutic apheresis for management of Lp (a) hyperlipoproteinemia SN Pokrovsky, OI Afanasieva, MV Ezhov Current Atherosclerosis Reports 22 (11), 68, 2020 | 21 | 2020 |
| The association of lipoprotein (a) and apolipoprotein (a) phenotypes with peripheral artery disease NA Tmoyan, MV Ezhov, OI Afanasieva, EA Klesareva, OA Razova, ... Terapevticheskii arkhiv 90 (9), 31-36, 2018 | 20 | 2018 |
| Association of lipoprotein (a) level with short-and long-term outcomes after CABG: The role of lipoprotein apheresis MV Ezhov, OI Afanasieva, LN Il'ina, MS Safarova, IY Adamova, ... Atherosclerosis Supplements 30, 187-192, 2017 | 20 | 2017 |
| Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins MV Ezhov, LN Il'ina, MS Safarova, OI Afanasieva, IY Adamova, ... Atherosclerosis Supplements 14 (1), 101-105, 2013 | 20 | 2013 |
| An immunoenzyme method for determining lipoprotein (a) OI Afanasieva, A IYu, GF Benevolenskaya, SN Pokrovsky Bull Exp Biol Med 120 (10), 398-401, 1995 | 20 | 1995 |
| Development of Immunosorbents for apoB‐Containing Lipoproteins Apheresis SN Pokrovsky, AV Sussekov, IY Adamova, OI Afanasieva, ... Artificial Organs 19 (6), 500-505, 1995 | 19 | 1995 |
| The association of lipoprotein (a) and circulating monocyte subsets with severe coronary atherosclerosis OI Afanasieva, AY Filatova, TI Arefieva, EA Klesareva, AV Tyurina, ... Journal of cardiovascular development and disease 8 (6), 63, 2021 | 18 | 2021 |
| Apolipoprotein (a) phenotype determines the correlations of lipoprotein (a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial … OI Afanasieva, MV Ezhov, OA Razova, MI Afanasieva, EA Utkina, ... Atherosclerosis 277, 477-482, 2018 | 18 | 2018 |
| Ig apheresis for the treatment of severe DCM patients SN Pokrovsky, MV Ezhov, MS Safarova, MA Saidova, VN Shitov, ... Atherosclerosis Supplements 14 (1), 213-218, 2013 | 18 | 2013 |
